MK 4621 / Merck (MSD) - LARVOL DELTA

[VIRTUAL] Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors (SITC 2020) - P1, P1/2 | "Conclusions The combination of intratumoral MK-4621 plus intravenous pembrolizumab had a manageable safety profile. At the highest dose level, modest antitumor activity was observed in patients treated with combination therapy."

Clinical • Late-breaking abstract • P1 data • Melanoma • Oncology • Solid Tumor

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. (PubMed, Cancer Immunol Immunother) - P1, P1/2 | "Patients treated with MK-4621 monotherapy or in combination with pembrolizumab experienced tolerable safety and modest antitumor activity, and there was evidence that MK-4621 activated the RIG-I pathway. At the doses tested, MK-4621 did not confer meaningful clinical benefit."

Combination therapy • Journal • Monotherapy • P1 data • Oncology • Respiratory Diseases • Solid Tumor

[VIRTUAL] Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors (SITC 2020) - P1, P1/2 | "Conclusions The combination of intratumoral MK-4621 plus intravenous pembrolizumab had a manageable safety profile. At the highest dose level, modest antitumor activity was observed in patients treated with combination therapy."

Clinical • Late-breaking abstract • P1 data • Melanoma • Oncology • Solid Tumor

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) (clinicaltrials.gov) - P1; N=30; Terminated; Sponsor: Merck Sharp & Dohme Corp.; Completed ➔ Terminated; Business Reasons

Clinical • Combination therapy • Monotherapy • Trial termination • Gastrointestinal Cancer • Oncology • Solid Tumor • MRI

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Merck Sharp & Dohme Corp.; Active, not recruiting ➔ Completed; N=72 ➔ 30

Clinical • Combination therapy • Enrollment change • Monotherapy • Trial completion • Gastrointestinal Cancer • Oncology • Solid Tumor

"$MRK Rig1 agonist MK-4621 #SITC20" (@JacobPlieth)

Oncology

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) (clinicaltrials.gov) - P1; N=72; Active, not recruiting; Sponsor: Merck Sharp & Dohme Corp.; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Monotherapy • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor